… Carlin, Casaburi, Emery, Mahler, and Make) had served on the previous guideline panel.
In addition to several conference calls, the panel met for one 2-day meeting to review the …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity,
mortality, and resource use worldwide. The goal of this Official American Thoracic Society (…

Background: Dyspnea is a common, distressing symptom of cardiopulmonary and neuromuscular
diseases. Since the ATS published a consensus statement on dyspnea in 1999, there …

To evaluate available clinical methods (self ratings and questionnaire) for rating dyspnea,
we (1) compared scores from the recently developed baseline dyspnea index (BDI) with the …

To improve the clinical measurement of dyspnea, we developed a baseline dyspnea index
that rated the severity of dyspnea at a single state and a transition dyspnea index that …

Currently available inhaled bronchodilators used as therapy for chronic obstructive pulmonary
disease (COPD) necessitate multiple daily dosing. The present study evaluates the long-…

Study objectives To examine and compare the efficacy and safety of salmeterol xinafoate, a
long-acting inhaledβ 2 -adrenergic agonist, with inhaled ipratropium bromide and inhaled …

This randomized controlled trial examined the benefits of combining an inhaled corticosteroid,
fluticasone propionate (F), with an inhaled long-acting β 2 -agonist, salmeterol (S), to treat …

Rationale: Indacaterol is the first once-daily, long-acting inhaled β 2 -agonist bronchodilator
studied in patients with chronic obstructive pulmonary disease (COPD). Objectives: To …